Bonini C, Ciceri F, Marktel S, Bordignon C
Telethon Institute for Gene Therapy (TIGET), Milano, Italy.
Vox Sang. 1998;74 Suppl 2:341-3. doi: 10.1111/j.1423-0410.1998.tb05440.x.
In allogeneic marrow transplantation (BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia and immune reconstitution. However, their use is limited by the risk of severe graft-vs-host disease (GvHD). Different strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. In the first pilot study, infusions of donor lymphocytes transduced with the Herpes Simplex virus thymidine kinase (HSV-tk) suicide resulted in anti-tumor activity in 50% of patients. Acute GvHD could be effectively controlled by ganciclovir-induced elimination of the transduced cells. If these results will be confirmed in larger studies, genetic manipulation of donor lymphocytes will increase efficacy and safety of allogeneic marrow transplantation.
在异基因骨髓移植（BMT）中，供体淋巴细胞在移植物抗白血病和免疫重建中都发挥着核心治疗作用。然而，其应用受到严重移植物抗宿主病（GvHD）风险的限制。人们已经研究了不同策略，以在避免GvHD风险的同时获得供体淋巴细胞带来的所有益处。在首个初步研究中，用单纯疱疹病毒胸苷激酶（HSV-tk）自杀基因转导的供体淋巴细胞输注使50%的患者产生了抗肿瘤活性。更昔洛韦诱导转导细胞消除可有效控制急性GvHD。如果这些结果能在更大规模研究中得到证实，对供体淋巴细胞进行基因操作将提高异基因骨髓移植的疗效和安全性。
